Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (203)	7/22/2004 2:16:53 PM
From: rkrw	Read Replies (1) of 684

Up to date as of their last reported quarter, as best as I can transcribe :-) VPHM, $40M MV, $108M cash and $130M debt CRGN, $255M, $407M cash, $240M debt ARNA, $108M, $145M cash AVGN, $70M, $87M cash CVTX, $430M, $490M cash, $375M debt INCY, $450M, $500M cash, $417M debt DRRX, $72M, $71M cash, $60M debt PRCS, $130M, $125M cash CRXA, $205M, $178M cash, $100M debt GENE, $275M, $225M cash, $125M debt IDEV, $265M, $208M cash, $72M debt NRGN, $215M, $175M cash

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next